First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
ALK rearrangement
Alectinib
Case report
Lung cancer
Pregnancy
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
11
12
2020
revised:
02
02
2021
accepted:
08
02
2021
pubmed:
3
4
2021
medline:
25
5
2021
entrez:
2
4
2021
Statut:
ppublish
Résumé
This is the first case report of a patient with ALK-rearranged metastatic lung adenocarcinoma who became pregnant during treatment with alectinib. A multidisciplinary team of gynecologists, neonatologists, oncologists, psychologists, and pharmacologists was set up to handle the case. According to patient's preference, the study drug was continued throughout pregnancy and the woman delivered a healthy baby girl at 35 weeks and 5 days of gestation. Fetal parameters remained normal during pregnancy. At birth, alectinib levels were 14 times higher in maternal plasma than in the fetus (259 versus 18 ng/mL). The average concentration of alectinib in the placenta was 562 ng/g. The baby was followed during her first 20 months, and no developmental anomalies were observed. After 32 months from diagnosis, the mother is well and in partial remission.
Identifiants
pubmed: 33795207
pii: S1556-0864(21)01705-6
doi: 10.1016/j.jtho.2021.02.005
pii:
doi:
Substances chimiques
Carbazoles
0
Piperidines
0
Protein Kinase Inhibitors
0
Anaplastic Lymphoma Kinase
EC 2.7.10.1
alectinib
LIJ4CT1Z3Y
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
873-877Informations de copyright
Copyright © 2021. Published by Elsevier Inc.